2025 Australia Cancer Diagnostics Market - 2024 Supplier Shares and Strategies, 2024-2029 Volume and Sales Segment Forecasts for over 40 Individual Tumor Markers

January 2025 | - | ID: 2E7788895EE5EN
Venture Planning Group

Abstracts

This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source, including 2024 supplier strategies and shares, and 2024-2029 volume and sales forecasts for major tumor markers. The report also provides a comprehensive lists of companies developing or marketing new technologies and products by test.The report is available by section, and can be customized to specific information needs and budget.
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.The companies analyzed in this report include:
Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Fujifilm Wako, Grifols, Hologic, Leica Biosystems, PerkinElmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, and others.